

Review

# Multiplex lateral flow immunoassay: an overview of strategies towards high-throughput point-of-need testing

Laura Anfossi\*, Fabio Di Nardo, Simone Cavalera, Cristina Giovannoli and Claudio Baggiani

<sup>1</sup> Department of Chemistry, University of Turin. Via Giuria, 5, I-10125 Turin, Italy

<sup>2</sup> Affiliation 2; e-mail@e-mail.com


\* Correspondence: laura.anfossi@unito.it; Tel.: +39-011-670-5219

**Abstract:** Simultaneous measurement of different substances from a single sample is an emerging issue to achieve efficient and high-throughput detection in several fields of application. Although immunoanalytical techniques have well-established and prevailing advantages over alternative screening analytical platforms, one of the incoming challenges for immunoassay is exactly multiplexing. The Lateral Flow Immunoassay (LFIA) is a leading immunoanalytical technique for onsite analysis thanks to its simplicity, rapidity and cost-effectiveness. Moreover, LFIA architecture is adaptable to multiplexing and therefore candidates as a possible answer to the pressing demand of multiplexing point-of-need analysis. The review present an overview of diverse approaches for multiplex LFIA, with a special focus on strategies based on new types of magnetic, fluorescent and colored labels.

**Keywords:** immunoassay; rapid test; point-of-care testing; immunochromatographic test.


## 1. Introduction

A lateral flow device (LFD) is a particular type of biosensor in which the recognition layer is fabricated onto the surface of a porous membrane. The membrane creates and sustains the flow of the sample and reagents by capillarity, and holds specific recognition elements that are confined in spatially defined zones of the membrane itself that are identified as reactive zones or detection sites (Fig 1). Usually, but not necessarily, the recognition elements are specific antibodies, and the biosensor relies on immunoassay principles, giving rise to the so-called 'lateral flow immunoassay' (LFIA), also named immunochromatographic (strip) test. The signal generates from reactions that involve the sample, the antibodies and a suitable probe and that take place in correspondence of the reactive zones of the membrane. Summarizing, the membrane, the probe and the antibodies used are equally important in determining the functionality of the biosensor.



**Figure 1.** Scheme of a general biosensor in the simpler arrangement and the corresponding elements of a lateral flow immunoassay biosensor.

The architecture of a typical LFD includes: the active porous membrane, additional membranes (i.e.: the sample, probe and adsorbent pads), and a structure that guarantee steadiness and consistency (Fig 2). As regard the probe, suitable bioselective reagents are linked to micro- or nano-materials that provide the signal and enable the detection of the reaction occurred onto the membrane. Most LFDs rely on visual readout; therefore, conventional labels are colored micro- or nanoparticles.



**Figure 2.** A typical LFIA strip: the strip architecture includes the detection membrane where selective antibodies are aligned to form the Test and Control lines, additional membranes (i.e.: the sample probe and adsorbent pads), a rigid structure and the probe.

The first LFIA was described and patented in the late 1970. Few years later, the LFD for ascertaining pregnancy (by measuring levels of the human hormone chorionic gonadotropin in urine) broke into the market giving rise to a paradigmatic change of the conception of care that led to the modern ideas of ‘point-of-care testing’ and, ultimately, of ‘personalized medicine’[1-2]. Since then, the LFIA has been widely spread in the clinical diagnostic both as a low-tech robust assay for applications in remote and/or resource poor environments and also for practitioners in day-to-day clinical work [3]. Meanwhile, the concept of ‘point-of-care’ testing has crossed the boundaries of medicine, so the general term ‘point-of-need testing’ is used to refer to portable analytical systems that can furnish the response where the analytical demand is posed. Accordingly, also the LFIA technology has found application in diverse fields, where its inherent advantages of simplicity, rapidity, cost-effectiveness and no requirement of equipment or technical expertise are crucial. Examples of the employment of LFIAs are found in the veterinary, forensic, food safety, and environmental analysis.

LFD are usually developed for the detection of a single compound per assay. However, simultaneous on-site measurement of different substances from a single sample is becoming more and more important [4]. The capability of multiplexing has several benefits, including improving the efficiency of testing and reducing costs, and is strongly requested for those applications in which advanced decision-making is requested or availability of sample is limited.


In order to improve the detection efficiency and achieve high-throughput detection, lots of efforts have been made on immunoassay, and in particular on the LFIA. Multiplexing LFIA (xLFIA) has been realized through several approaches, which can be divided in two main groups: multiplexing strategies involving a modification of the architecture of the device and multiplexing strategies based on the use of suitable probes.

Compared to other immunoanalytical techniques, such as those carried out in microplate format (i.e.: ELISA, Enzyme Linked ImmunoSorbent assay), the LFIA candidates itself as particularly suited for enabling multiplex analysis. Indeed, the architecture of the LFD constitutively includes the possibility of aligning more than one detection site in a single analytical device (Fig 2). As a rule, a LFD includes at least two reaction sites, one that respond to the compound to be detected (called Test line), and a second reaction site that is used as an internal control to ensure correct operation of the device (Control line) [5]. Binding events at the two reaction sites usually happen

independently from each other, although involving one sample and one probe. Therefore, multiplexing can be simply conceived as appending further reaction sites along the length of the strip (provided that no reciprocal interference between the different reactions exists). The spatial separation of multiple detection sites requires the minimum manipulation of the assay architecture (Fig 3a) and is the far most popular way to achieve multiplexing in LFIA. However, interpreting the qualitative results of a multi-zone lateral flow assay is not as simple as that of a conventional single-parameter assay. An increase in the number of analytes of interest interferes with the identification of the closely spaced test zones. Attempting to mitigate this issue by increasing the distance between these zones obviously leads to increased consumption of sample and membrane materials, as well as increased assay times [6].

Along with the spatial separation of detection sites in one strip, the separation of reaction sites using individual strips arranged in an 'array-like' format (Fig. 3b) has been exploited also widely. This second approach impacts again on the architecture of the assay, with even lower constraints than the first. In particular, several assays are realized in parallel onto different strips that share only the sample. As a consequence, no risk of reciprocal interference exist between assays. Nevertheless, the costs of fabrication and the volume of sample needed increase proportionally with the number of analytes being detected.


Strategies to multiplexing that have developed primary for other immuno-analytical techniques can be transferred to setting xLFIA. For instance, the development of antibodies or other recognition elements that are group-specific to contaminants can be used to develop detection methods for a class of structurally related compounds (Fig. 3c). Besides, labels that provide distinguishable signals can be exploited to individually detect different compounds in a single reaction site (Fig 3d). This last approach requires different labels that can be detected by one detection system, such as, for examples, fluorescent labels that are excited by a single source while showing different emissions, or multi-chromatic labels. Several nanomaterials with suitable features (namely, quantum dots, QD, colored latex beads, lysosome-encapsulated dyes, etc) have been used to design such kind of xLFIA. Nevertheless, they have been mostly employed to facilitate the identification of spatially separated detection sites, rather than for enabling multiple detection in a single reaction site.



**Figure 3.** Strategies for multiplexing LFIA by: a) spatially separate detection sites in a single strip; b) aligning several strips in an array format; c) exploiting signal reporters that provide different signals; and d) using broad-selective antibodies able to bind to several compounds in a class.

All above described approaches are reciprocally independent and can be integrated in order to tremendously enlarge the number of compounds that can be analyzed simultaneously by a single LFIA device (Fig 4). Conceptually, rolling two, three and even all four multiplexing approaches in one device is a feasible way towards high-throughput analytical systems, however, at the expenses of simplicity and operability by untrained personnel, which is a distinct trait of the LFIA technique. The design of high-throughput multiplexing strategies should be balanced with guaranty of retaining the primary benefits of the technique, such as its rapidness, on-field applicability, simplicity of execution and detection, and cost-effectiveness.

This review will critically discuss the approaches for multiplexing LFIA based on engineering (i) the architecture of the device and (ii) the probe design; and will focus on perspectives in the use of new nanomaterials as efficient versatile labels for enabling xLFIA in a single strip.



**Figure 4.** Approaches to multiplexing LFIA can be exploited separately (single 'x' multiplexing level) or combining two (x2), three (x3) or even four (x4) of them. Combinations highlighted in colors have been reported in literature, while multiplexing strategies theoretically realizable but not yet reported are shown in grey.

## 2. Strategies for multiplexing LFIA

### 2.1. One-strip xLFIA: spatial separation of detection sites

The far most popular strategy to multiplexing LFIAs is the design of several test lines or dots on an immunochromatographic strip using gold nanoparticles (GNP), quantum dots, or colored/fluorescence microspheres as labels. A shortcoming of fluorescence nanoparticles is that they require using an external device for the excitation, so colored nanoparticles that can be visualized by the naked eye have been investigated more extensively. Therefore, the approach based on drawing two or more lines in a single strip and using GNP as the label has been more largely reported [7-17]. In particular, the approach has been applied for the simultaneous detection of food contaminants, such as mycotoxins [7,13,16,17], antibiotics [18,9,12], and pesticides [10,14,15]. Anyway, the number of lines that can be arranged in a single strip is limited, if not resorting to strip elongation. And strip elongation requires increasing the amount of sample to be employed and the time for completing the assay. Furthermore, reproducibility of the properties of the nitrocellulose membrane and, as a consequence of the flow, becomes triggering while increasing the strip length. The maximum number of lines that have been included in a single strip is six (comprising the Control line), which means that up to five different compounds were detected simultaneously

[8,14,15]. Most frequently, two-three analytes are detected by one-strip xLFIA [7,9,10, 11,12,13,16,17].

A feasible way to extremely increase the number of spatially separated detection sites is the conversion of the detection site itself from the line-shaped to the dot-shaped. Indeed, the number of individual dots that can be arranged in a strip is much more larger than the number of lines. As an example, the work of Taranova et al. reported the fabrication of a LFD in which the test zone of the nitrocellulose support comprised a microarray spotted with up to 32 capturing antigens [18]. Correspondently, thirty-two different drugs of abuse were simultaneously detected in urine by means of the xLFIA. The approach greatly improved productivity of the assay, however at the expenses of the robustness of the assay result, because the smaller the detection site, the higher is the impact of flow inhomogeneity on the generation of the signal.

## 2.2. Array of strips

Several individual strips can be arranged in a special holder, also designed as to collect one sample and distribute it between several strips. The sample flows in parallel on each strip, which in turn can hold one or more Test lines. Advantages of this approach rely in the large multiplexing capability and in the absence of reciprocal interference between assays that happen independently on individual strips. Indeed, each assay can be developed singularly and then put together without requiring any further optimization [19]. As an illustration of the multiplexing ability of the 'array of strips' approach, Hong et al. demonstrated the simultaneous detection of 10 different antibodies by using a 10-channel up-converting phosphor technology-based lateral flow (TC-UPT-LF). In that study, after optimization one by one, each strip was integrated into a TC-UPT-LF disc to profile antibodies against *Yersinia pestis*. Similarly, the 10-channel disc configuration was employed to simultaneously detect ten foodborne pathogens [20]. The 'array of strips' approach is popular among manufacturers and is commonly found in drug of abuse testing devices [21-22].

LFDs implementing the 'array of strips' strategy are well suited for applications in which large volumes of samples are available. Usually, each strip requires 50-100  $\mu\text{l}$  of liquid to complete the assay and the amount of sample required increases while the number of strip increases. In fact, such kind of LFDs are used for the onsite rapid detection of urinary and salivary metabolites [21-24], thus applies to biological fluids that can be collected non-invasively. Similarly, their usage can be envisaged for high-throughput analysis in food safety assessment where the amount of sample available is usually not a restraint.

Besides requiring large volumes of the sample, the 'array of strips' approach is also costly compared to other multiplexing strategies employing the same bio-reagents and probes. Costs of LFD production includes materials and chemicals used to prevent matrix interference and to guarantee long-term stability. Therefore, the higher the number of strips is the higher the cost of the device.

A tentative to overcome limitations due to sample availability and cost of production has been proposed by Schenk et al., who described the first steps aimed at developing a 'multi-channel strip' for the simultaneous detection of the lipopolysaccharides of *Salmonella typhimurium* and *Salmonella enteritidis* [25]. In their work, authors structured channels in the nitrocellulose membrane by means of laser ablation. In this way, four distinct tracks of porous material were formed in the width of a usual strip, and each of the channel was operated as a distinct strip. Preliminary, studies on the wicking properties of the laser ablated nitrocellulose showed that a minimum channel width and a minimum barrier thickness between channels are required for obtaining reproducible flowing [26]. Although these works represent an interesting attempt of expanding the multiplexing capability of the one-strip LFIA, the readability of assay result should be also carefully considered when miniaturizing point-of-need testing systems that are meant to be used by untrained operators.

## 2.3. Multiplexing LFIA based on the probe

Here, the probe is a conjugate between a recognition element, which is a moiety able to bind to reagents forming Test and Control lines and to the analyte, and a label, that generates a detectable signal (also referred as the signal reporter). Adapting both the recognition element and the signal reporter allows for achieving multiplexing (Fig. 3c-d).

In one sense, broad-specific recognition elements have been developed with the aim of detecting several compounds in a group or a class. As a matter of fact, class-selective antibodies have been prepared and used to measure several analytes (within a class of compounds) by means of LF devices [27-29]: Zhang et al. developed a monoclonal antibody, which was able to recognize three major ochratoxins, and based on this mAb, they proposed a LFIA for the simultaneous detection of the three hazardous substances. [27]. Similarly, Xie et al. generated a monoclonal antibody that equally recognizes avermectin and ivermectin and employed it for setting up a dual LFIA [28]. Notably, Wang R. et al. reported a xLFIA for measuring up to 7  $\beta$ -agonists in a single run by using a monoclonal that recognized clenbuterol and its analogues [29].

However, this approach needs complicated processes for the production of the antibodies and is confined to applications in which the useful information is the presence of any of the compounds in the class (or their sum), rather than the identification of one specific compound, which significantly reduce their practical use.

The use of various labels (e.g., enzymes, fluorophores, and nanoparticles) can be regarded as a viable alternative for xLFIA multiplexing. Indeed, the exploitation of labels providing distinguishable signals allows differentiating various complexes that are formed at the same site (i.e. at a single Test line). This approach has been seldom used [30-33]. Wang W. et al. proposed a smart multiplexing strategy based on the different kinetics of horseradish peroxidase and alkaline phosphatase to obtain a time-resolved chemiluminescence detection [30]. Accordingly, two antibodies (selective to ractopamine and clenbuterol, respectively) were mixed to form a single Test line and the presence of any one of the two analytes was revealed by the same chemiluminescence signal, while the time of the signal generation allowed for distinguishing among the analytes. Likewise, Wang C. et al. exploited two QD emitting at different wavelengths as distinguishable labels and used them to tag specific antibodies directed towards two tumour markers in a the sandwich-type immunoassay. The capture antibodies were placed onto the nitrocellulose membrane to form a single Test line and the two tumour markers were recognized by the colour of the QD photoluminescence [31].

Multiplex detection in the 'single Test line' format associated to colorimetric detection has been described also [32-33]. In the approach proposed by Yen et al., trichromatic silver nanoparticles were exploited for the simultaneous detection of different viruses by a sandwich xLFIA [32]. In particular, orange, red and green silver nanoparticles were employed to set a xLFIA. However, the colour of the mixed signal reporters made almost impossible to evaluate the co-occurrence of analytes by the naked-eye. Nevertheless, the recognition of viruses was made possible through digitally processing the images of the strips.

Despite attracting, the integration of probes providing variable signals as a function of the analyte to be detected, shows some limitations in the potential application for on-field analysis. In particular, the need of some equipment to elaborate the assay result increases costs and limits viability. In the attempt of mitigating this weakness, our group developed a dichromatic xLFIA that used blue and red gold nanoparticles as the labels [33]. We prepared GNP that differed in shape (and therefore in the wavelength of the surface plasmon resonance peak) to tag two antibodies selective for two major mycotoxins (aflatoxin B1 and fumonisin B1), respectively, and developed a xLFIA in the competitive format to detect simultaneously the two toxic compounds. Antigens of each mycotoxins were mixed and dropped onto the nitrocellulose membrane to fabricate a single Test line. As a result of the simultaneous binding of the red- and blue-labelled antibodies to the mixed antigens, the Test line appeared purple. Upon addition of one mycotoxin, the binding of the corresponding red-(blue) labelled antibody was inhibited at the Test line, which thus appeared of the complementary colour, namely blue (red). The simultaneous presence of both contaminants produced the complete disappearance of the Test line, due to the contemporary inhibition of the binding of both red- and blue- labelled antibodies. Therefore, the contamination due to each

mycotoxin was visually detected and discriminated based on a pre-defined colour code. In this case, digital processing of images enabled also (semi-)quantitative analysis. A further benefit of using labels that show primary colours, besides facilitating the visual reading of results, resided in the simplicity of image processing through the RGB data analysis.

Summarizing, the search for new labels that are able to provide variable signals represent a chance to expand multiplexing capability of LFIA, especially if in combination with other multiplexing strategies. However, the realistic usage of new probes is strictly dependent on their easily integration into the LFIA systems (i.e.: ability to freely flow through porous membranes, absence of non-specific interaction with typical LFD materials, etc). Furthermore, new probes are required to guarantee simplicity and rapidity to the LFIA detection step.

#### 2.4. *x<sup>n</sup>LFIA: integration of 'multiple' multiplexing strategies in a single LFIA device*

Ideally, each multiplexing approach described above can be combined with others to enhance further the productive potential of LFIA.

The integration of two (x2LFIA) and, sometimes, three different strategies (x3LFIA) was reported enabling high-throughput analysis. For instance, dozens of compounds were detected within minutes, moreover requiring few microliters of the sample and no equipment.

In this sense, broad-selective antibodies have been used in combination with the manipulation of the device architecture for the detection of antibiotic families in milk [34-35]. Wang C et al. used three class-selective antibodies and latex beads and colloidal gold as colored reporters to detect twelve sulfonamide, eighteen quinolone and six tetracycline residues by a single LFD [34]. In this work, multicolored labels were employed to simplify the identification of the detection sites and did not contribute to further increasing multiplexing. Han et al. also exploited group-selective antibodies for measuring three classes of antimicrobial agents combined with employing GNP as the label [35]. In these examples, the spatial separation of detection sites and the broad-specificity of antibodies were employed as orthogonal resources (x2LFIA) for expanding the multiplexing quality of the device. As a result, they achieved the ability of simultaneously detect up to thirty-six compounds by a single device and using just few microliters of sample.

Multiplex LFIA realized through the spatial separation of lines in one strip has been combined also with the exploitation of innovative labels, such as up-converting phosphor reporter particles [36-37], magnetic nanobeads [38-39], enzymes triggering chemiluminescence [40] and near-infrared fluorescence label [41]. In the last paper, the detection of three classes of antimicrobial agents in a single run was achieved by combining the use of three broad-specific antibodies and the spatial separation of three lines in one strip. Therefore, a x2LFIA was realized, increasing the total number of target compounds that were detected by a single device. As a further advantage, the spatial separation of detection sites allowed for individually detect the three classes of antibiotics, thus enabled their recognition.

Most devices in the array format not only incorporate several strips, but each strip is designed for the detection of more than one compound. In particular, LFD for detecting drugs of abuse are designed in the 'array of strips' configuration, in which individual strips show several spatially separated detection sites and, in some cases, also use class-selective antibodies. The combination of the three strategies (x3LFIA) gave rise to LFDs that are able to simultaneously detect and identify of up to 20 different compounds, with limited requirement for increasing the sample volume [22].

### 3. New labels for xLFIA

Considered that LFDs are intended for being operated by untrained personnel, often multicolored labels have been used to facilitate distinguishing the various detected analytes. In particular, spatially separated detection sites were identified not only based on positioning of the line along the strip, but also on the specific color of the probe used [34, 42-44].

The same intent of simplifying analyte identification by means of labels with different optical properties has been pursued in several works based on the use of quantum dots (QD) [6, 45-48].

Apparently, QD are ideal labels for xLFIA, as they emit light at different wavelengths with narrow and intense emission peaks, while the excitation band is wide; therefore, differently colored emissions are obtained upon excitation by a single light source. Despite this beneficial characteristic, QD suffer for several drawbacks that have limited their wide employment as labels for xLFIA, such as: low hydrophilicity, lack of functional groups for conjugation to biomolecules (and especially to recognition elements), poor long-term stability, and strong non-specific interactions with materials typically constituting LFDs [49]. Attempts have been made to overcome some of these limitations, including coating QD with amphiphilic polymers or encapsulating them in silica nanoparticles. These strategies permitted to introduce chemical functionalities to QD and to increase their stability and water compatibility, however at the expenses of their fluorescence quantum yield [50]. Furthermore, QD are made from toxic heavy metals, so they are being progressively replaced by fluorescent carbon nanomaterials (namely, carbon quantum dots, CQD), which are organic nanoparticles with similar optical properties and less toxicity compared to inorganic QD. Additionally, CQD are hydrophilic and can be prepared as stable aqueous suspensions. They are synthesized from various carbonous precursors [51]; therefore, CQD with intrinsic chemical functionalities suitable for their conjugation to biomolecules can be obtained from appropriate precursors [52-53]. The first xLFIA exploiting CQD as the label has been described by Fang et al. [54]. In their work, authors developed a fluorescence LFD for detecting three tumor markers in a single analysis, in which three lines were drawn in one strip and multicolor CQD were used as the labels to recognize the different biomarkers. Again, the multi-chromaticity served for identification purposes rather than for enlarging the multiplexing quality of the device. Nevertheless, this new class of fluorescent nanomaterials candidates itself as a very promising labels for future xLFIA development.

Magnetic nanolabels have permitted the development of multiplex methods that cannot be realized with colored or fluorescent labels. The potential of magnetic nanoparticles (MNP) as labels derives from the fact that they, unlike optical labels, can be easily detected inside 3D opaque porous structures, such as within the thickness of the LFIA membrane. The opportunity of measuring non only the portion of nanolabels that is located onto the surface but the whole amount of labels distributed in the width of the membrane determines a significant increase of the assay sensitivity. Based on this principle, Lu et al. prepared immuno-magnetic probes by covalently linking MNP to specific antibodies directed towards two tumor markers. The immuno-magnetic probes were included in a dual LFD also comprising a single strip with two spatially separated Test lines. The LFD permitted the simultaneous detection of the two biomarkers with high diagnostic sensitivity and specificity [38]. An original quantification of MNP by non-linear magnetization proposed by Nikitin et al. allowed for further increase the sensitivity of detection of immuno-magnetic assays [39]. The prospect of the novel quantification method was illustrated by four different rapid bio-sensing systems, including a xLFIA for the simultaneous detection of three model compounds. Also there, three spatially separated Test lines were created on a single strip and the MNP were used as the label for quantification. Benefits of MNP in terms of increased sensitivity are counterbalanced by the requirement of some external devices for the detection and, therefore, should be considered attentively, especially for onsite and low-resource setting applications.

#### 4. Conclusions

The rapid evolution of lab-based analytical techniques, in particular the tremendous technical improvement of the liquid chromatography coupled to tandem mass spectrometry systems, is posing a new challenge to analytical methods traditionally employed as first level screening methods, such as those using biosensors. The massive sample processing and the intrinsic multiplexing capability are making lab-based techniques very attracting, also because accurate and precise results are obtained in a reasonable time and with acceptable costs. Therefore, the incoming progress of instrumental techniques represents a threat for the predominance of immuno-analytical techniques, especially when several data are required to reach a meaningful information. Increasing multiplexing ability is then a need rather than a possibility for the future of immunoassay.



Attempts aimed at multianalyte detection in microplate-based immunoassay have been described, which exploit all approaches above discussed, however due to the requirement for specific instrumental set-up for quantifying the output of the assays, their application remains unpractical. Conversely the LFIA platform is particularly adaptable for multiplexing purposes, hence the research is tremendously active in this field and several solutions enabling the simultaneous detection of few to dozens compounds have been proposed insofar. Strategies described are diverse and range from simply juxtaposing several strips in a multichannel holder to more sophisticated approaches based on new signal reporters. However, considering the demand for increasing productivity of biosensors in general and, of LFIA in particular, the number of applications is destined to grow further in the next future.

The exploitation of innovative signal reporters combined to technological advances that make the 'instrumental detection' feasible through generic and widely available devices (such as smartphones) opens new perspectives to the field. Contemporaneous efforts should be devoted to harmonize protocols and sample preparation for enabling the parallel execution of different assays and to minimize production costs.

Finally, the scope of expanding multiplexing capability cannot be pursued without preserving those characteristics that make the LFDs best suited for fitting ASSURED (Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and Deliverable to end-users) criteria [1] and that have decreed their current success and their expanding growth.

**Author Contributions:** For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used "conceptualization, X.X. and Y.Y.; methodology, X.X.; software, X.X.; validation, X.X., Y.Y. and Z.Z.; formal analysis, X.X.; investigation, X.X.; resources, X.X.; data curation, X.X.; writing—original draft preparation, X.X.; writing—review and editing, X.X.; visualization, X.X.; supervision, X.X.; project administration, X.X.; funding acquisition, Y.Y.", please turn to the [CRediT taxonomy](#) for the term explanation. Authorship must be limited to those who have contributed substantially to the work reported.

**Funding:** This research received no external funding

**Acknowledgments.**

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. St John, A.; Price, C.P. Existing and Emerging Technologies for Point-of-Care Testing Clin Biochem Re., 2014, 35, 155–167
2. Dhawan, A. Point-of-Care Technologies: An Evolution in Personalized Healthcare. IEEE Life Sciences eNewsletter available at: <https://lifesciences.ieee.org/lifesciences-newsletter/2013/january-2013/point-of-care-technologies-an-evolution-in-personalized-healthcare/> (accessed on 15 September 2018)
3. O'Farrell, B. Lateral Flow Technology for Field-Based Applications-Basics and Advanced Developments Top Companion Anim Med 2015, 30, 139–147
4. Dincer, C.; Bruch, R.; Kling, A.; Dittrich, P.S.; Urban, G.A. Multiplexed Point-of-Care Testing – xPOCT Trends Biotechnol 2017, 35,728-742
5. Sajid, M.; Kawde, A-N.; Daud, M. Designs, formats and applications of lateral flow assay: A literature review. J Saudi Chem Soc 2015, 19, 689-705
6. Taranova, N.A.; Berlina, A.N.; Zherdev, A.V.; Dzantiev, B.B. 'Traffic light' immunochromatographic test based on multicolor quantum dots for the simultaneous detection of several antibiotics in milk. Biosens Bioelectron. 2015, 63, 255-261. DOI: 10.1016/j.bios.2014.07.049.
7. Song, S.; Liu, N.; Zhao, Z.; Ediage, E.N.; Wu, S.; Sun, C.; De Saeger, S.; Wu A. Multiplex Lateral Flow Immunoassay for Mycotoxin Determination Anal Chem 2014, 86, 4995-5001
8. Peng, J.; Wang, Y.; Liu, L.; Kuang, H.; Liand, A.; Xu C. Multiplex lateral flow immunoassay for five antibiotics detection based on gold nanoparticle aggregations. RSC Adv., 2016, 6, 7798-7805

9. Zhang, M-Z.; Wang, M-Z.; Chen, Z-L.; Fang, J-H.; Fang, M-M.; Liu, J.; Yu, X-P. Development of a colloidal gold-based lateral-flow immunoassay for the rapid simultaneous detection of clenbuterol and ractopamine in swine urine. *Anal Bioanal Chem*, 2009, 395, 2591–2599
10. Wang, Q.; Liu, Y.; Wang, M.; Chen, Y.; Jiang, W. A multiplex immunochromatographic test using gold nanoparticles for the rapid and simultaneous detection of four nitrofurantoin metabolites in fish samples. *Anal Bioanal Chem*. 2018, 410, 223-233. DOI: 10.1007/s00216-017-0714-y.
11. Oku, Y.; Kamiya, K.; Kamiya, H.; Shibahara, Y.; Li, T.; Uesaka, Y. Development of oligonucleotide lateral-flow immunoassay for multi-parameter detection. *J Immunol Met* 2001, 258, 73–84
12. Sun, Y.; Yang, J.; Yang, S.; Sang, Q.; Teng, M.; Li, Q.; Deng, R.; Feng, L.; Hu, X.; Zhang, G. Development of an immunochromatographic lateral flow strip for the simultaneous detection of aminoglycoside residues in milk *RSC Adv*, 2018, 8, 9580-9586, DOI: 10.1039/C8RA01116H
13. Wang, Y-K.; Shi, Y-B.; Zou, Q.; Sun, J-H.; Chen, Z-F.; Wang, H.; Shu-Qing Li, S-Q.; Yan, Y-X. Development of a rapid and simultaneous immunochromatographic assay for the determination of zearalenone and fumonisin B1 in corn, wheat and feedstuff samples. *Food Control* 2013, 31, 180-188
14. Liu, B.; Gong, H.; Wang, Y.; Zhang, X.; Li, P.; Qiu, Y.; Wang, L.; Hua, X.; Guo, Y.; Wang, M.; Liu, F.; Liu, X.; Zhang, C. A gold immunochromatographic assay for simultaneous detection of parathion and triazophos in agricultural products *Ana. Methods*, 2018, 10, 422-428, DOI: 10.1039/C7AY02481A
15. Xing, C.; Liu, L.; Song, S.; Feng, M.; Kuang, H.; Xu, C. Ultrasensitive immunochromatographic assay for the simultaneous detection of five chemicals in drinking water *Biosens Bioelectron*, 2015, 66, 445-453
16. Li, X.; Li, P.; Zhang, Q.; Li, R.; Zhang, W.; Zhang, Z.; Ding, X.; Tang, X. Multi-component immunochromatographic assay for simultaneous detection of aflatoxin B1, ochratoxin A and zearalenone in agro-food. *Biosens Bioelectron*, 2013, 49, 426-432
17. Chen, Y.; Chen, Q.; Han, M.; Zhou, J.; Gong, L.; Niu, Y.; Zhang, Y.; He, L.; Zhang, L. Development and optimization of a multiplex lateral flow immunoassay for the simultaneous determination of three mycotoxins in corn, rice and peanut. *Food Chem*, 2016, 213, 478-484. DOI: 10.1016/j.foodchem.2016.06.116.
18. Taranova, N.A.; Byzova, N.A.; Zaiko, V.V.; Starovoitova, T.A.; Vengerov, Y.Y.; Zherdev, A.V.; Dzantiev, B.B. Integration of lateral flow and microarray technologies for multiplex immunoassay: application to the determination of drugs of abuse *Microchim Acta* 2013, 180, 1165–1172
19. Hong, W.; Huang, L.; Wang, H.; Qu, J.; Guo, Z.; Xie, C.; Zhu, Z.; Zhang, Y.; Du, Z.; Yan, Y.; Zheng, Y.; Huang, H.; Yang, R.; Zhou, L. Development of an up-converting phosphor technology-based 10-channel lateral flow assay for profiling antibodies against *Yersinia pestis* *J Microbiol Met*, 2010, 83 133–140
20. Zhao, Y.; Wang, H.; Zhang, P.; Sun, C.; Wang, X.; Wang, X.; Yang, R.; Wang, C.; Zhou, L. Rapid multiplex detection of 10 foodborne pathogens with an up-converting phosphor technology-based 10-channel lateral flow assay. *Sci Rep*, 2016, 6, 21342, DOI: 10.1038/srep21342.
21. Carrio, A.; Sampedro, C.; Sanchez-Lopez, J. L.; Pimienta, M.; Campoy, P. Automated Low-Cost Smartphone-Based Lateral Flow Saliva Test Reader for Drugs-of-Abuse Detection Sensors, 2015, 15, 29569-29593; DOI:10.3390/s151129569
22. <https://www.alfscientific.com/products/multi-drug-urine-tests/> (accessed 18 September 2018)
23. <https://www.medacx.co.uk/products/drug-abuse-tests/salivascreen-doa> (accessed 18 September 2018)
24. <http://www.medicalexpo.com/prod/prima-lab-sa/product-99429-706870.html> (accessed 18 September 2018)
25. Schenk, F.; Weber, P.; Vogler, J.; Hecht, L.; Dietzel, A.; Gauglitz, G. Development of a paper-based lateral flow immunoassay for simultaneous detection of lipopolysaccharides of *Salmonella* serovars *Anal Bioanal Chem*, 2018, 410, 863–868
26. Hecht, L.; van Rossum, D.; Dietzel, A. Femtosecond-laser-structured nitrocellulose membranes for multi-parameter Point-of-Care tests *Microelectron Eng*, 2016, 158, 52-58
27. Zhang, M.; Yan, L.; Huang, Q.; Bu, T.; Yu, S.; Zhao, X.; Wang, J.; Zhang, D. Highly sensitive simultaneous detection of major ochratoxins by an immunochromatographic assay *Food Control*, 2018, 84, 215-220
28. Xie, Z.; Kong, D.; Liu, L.; Song, S.; Kuang, H. Development of ic-ELISA and lateral-flow immunochromatographic assay strip for the simultaneous detection of avermectin and ivermectin *Food Agric Immunol*, 2017, 28, 439-451, DOI: 10.1080/09540105.2017.1293016
29. Wang, R.; Zhang, W.; Wang, P.; Su, X. A paper-based competitive lateral flow immunoassay for multi  $\beta$ -agonist residues by using a single monoclonal antibody labelled with red fluorescent nanoparticles *Microchim Acta*, 2018, 185, 191-198 DOI: 10.1007/s00604-018-2730-9

30. Wang, W.; Su, X.; Ouyang, H.; Wang, L.; Fu, Z. A novel immunochromatographic assay based on a time-resolved chemiluminescence strategy for the multiplexed detection of ractopamine and clenbuterol. *Anal Chim Acta* 2016, 917, 79-84. DOI: 10.1016/j.aca.2016.03.001.
31. Wang, C.; Hou, F.; Ma, Y.. Simultaneous quantitative detection of multiple tumor markers with a rapid and sensitive multicolor quantum dots based immunochromatographic test strip. *Biosens Bioelectron* 2015, 68, 156-162. DOI: 10.1016/j.bios.2014.12.051.
32. Yen, C-W.; de Puig, H.; Tam, J.O.; Gómez-Márquez, J.; Bosch, I.; Hamad-Schifferli, K.; Gehrke, L. Multicolored silver nanoparticles for multiplexed disease diagnostics: distinguishing dengue, yellow fever, and Ebola viruses Lab Chip, 2015, 15, 1638-1641
33. Di Nardo, F.; Alladio, E.; Baggiani, C.; Cavallera, S.; Giovannoli, C.; Spano, G.; Anfossi, L. Colour-encoded lateral flow immunoassay for the simultaneous detection of aflatoxin B1 and type-B fumonisins in a single Test line. *Talanta* 2019, 192, 288-294. DOI: 10.1016/j.talanta.2018.09.037
34. Wang, C.; Li, X.; Peng, T.; Wang, Z.; Wen, K.; Jiang, H. Latex bead and colloidal gold applied in a multiplex immunochromatographic assay for high-throughput detection of three classes of antibiotic residues in milk. *Food Control*, 2017, 77, 1-7
35. Han, S.; Zhou, T.; Yin, B.; He, P. A sensitive and semi-quantitative method for determination of multi-drug residues in animal body fluids using multiplex dipstick immunoassay. *Anal Chim Acta*, 2016, 927, 64-71. DOI: 10.1016/j.aca.2016.05.004.
36. Corstjens, P. L. A. M.; de Dood, C. J.; van der Ploeg-van Schip, J. J.; Wiesmeijer, K. C.; Riuttamäki, T.; van Meijgaarden, K. E.; Spencer, J. S.; Tanke, H. J.; Ottenhoff, T.H.M.; Geluk, A. Lateral flow assay for simultaneous detection of cellular- and humoral immune responses. *Clin Biochem*, 2011, 44 1241–1246
37. Hao, M.; Zhang, P.; Li, B.; Liu, X., Zhao, Y.; Tan, H.; et al. Development and evaluation of an up-converting phosphor technology-based lateral flow assay for the rapid, simultaneous detection of *Vibrio cholerae* serogroups O1 and O139. *PLoS ONE*, 2017, 12, e0179937. DOI: 10.1371/journal.pone.0179937
38. Lu, W.; Wang, K.; Xiao, K.; Qin, W.; Hou, Y., Xu, H.; Yan, X.; Chen, Y.; Cui, D.; He, J. Dual Immunomagnetic Nanobeads- Based Lateral Flow Test Strip for Simultaneous Quantitative Detection of Carcinoembryonic Antigen and Neuron Specific Enolase. *Sci.c Rep.*, 2017, 7, 42414, DOI: 10.1038/srep42414
39. Nikitin, M. P.; Orlov, A. V.; Znoyko, S. L.; Bragina, V. A.; Gorshkov, B. G.; Ksenevich, T. I.; Cherkasov, V. R.; Nikitin, P. I. Multiplex biosensing with highly sensitive magnetic nanoparticle quantification method. *J Magnetism Magnet Mat* 2018, 459, 260-264
40. Zangheri, M.; Di Nardo, F.; Anfossi, L.; Giovannoli, C.; Baggiani, C.; Roda, A., Mirasoli, M. A multiplex chemiluminescent biosensor for type B-fumonisins and aflatoxin B1 quantitative detection in maize flour. *Analyst* 2015, 140, 358-365. DOI: 10.1039/c4an01613k.
41. Chen, Y.; Chen, Q.; Miaomiao Han, M.; Liu, J.; Zhao, P.; He, L.; Yuan Zhang, Y.; Niu, Y.; Yang, W.; Zhang, L. Near-infrared fluorescence-based multiplex lateral flow immunoassay for the simultaneous detection of four antibiotic residue families in milk *Biosens Bioelectron*, 2016, 79, 430-434
42. Lee, S.; Mehta, S.; Erickson, D. Two-Color Lateral Flow Assay for Multiplex Detection of Causative Agents Behind Acute Febrile Illnesses *Anal Chem*. 2016, 88, 8359–8363. DOI: 10.1021/acs.analchem.6b01828
43. Sastre, P.; Pérez, T.; Costa, S.; Yang, X.; Räber, A., Blome, S.; Goller, K.T.; Gallardo, C.; Tapia, I.; García, J.; Sanz, A.; Rueda, P. Development of a duplex lateral flow assay for simultaneous detection of antibodies against African and Classical swine fever viruses. *J. Vet. Diagn Investig* 2016, 28, 543 –549
44. Di Nardo, F.; Baggiani, C.; Giovannoli, C.; Spano, G.; Anfossi, L. Multicolor immunochromatographic strip test based on gold nanoparticles for the determination of aflatoxin B1 and fumonisins *Microchim Acta* 2017, 184, 1295-1304 DOI: 10.1007/s00604-017-2121-7
45. Gharaat, M.; Sajedi, R. H.; Shanehsaz, M.; Jalilian, N.; Mirshahi, M.; Gholamzad, M. A dextran mediated multicolor immunochromatographic rapid test strip for visual and instrumental simultaneous detection of *Vibrio cholera* O1 (Ogawa) and *Clostridium botulinum* toxin A *Microchim Acta* 2017, 184, 4817–4825 DOI: 10.1007/s00604-017-2527-2
46. Xiao, K.; Wang, K.; Qin, W.; Hou, Y., Lu, W.; Xu, H., Wo, Y.; Cui, D. Use of quantum dot beads-labeled monoclonal antibody to improve the sensitivity of a quantitative and simultaneous immunochromatographic assay for neuron specific enolase and carcinoembryonic antigen. *Talanta* 2017, 164, 463-469. DOI: 10.1016/j.talanta.2016.12.003.
47. Beloglazova, N. V.; Sobolev, A.M.; Tessier, M. D.; Hens, Z.; Goryacheva, I. Y.; De Saeger, S. Fluorescently labelled multiplex lateral flow immunoassay based on cadmium-free quantum dots *Methods* 2017, 116, 141-148

48. Foubert, A.; Beloglazova, N. V.; Gordienko, A.; Tessier, M. D.; Drijvers, E.; Hens, Z.; De Saeger, S. Development of a Rainbow Lateral Flow Immunoassay for the Simultaneous Detection of Four Mycotoxins. *J Agric Food Chem.* 2017, 65, 7121-7130. DOI: 10.1021/acs.jafc.6b04157
49. Di Nardo, F.; Anfossi, L.; Giovannoli, C.; Passini, C.; Gofman, V. V.; Goryacheva, I.Y.; Baggiani, C. A fluorescent immunochromatographic strip test using Quantum Dots for fumonisins detection. *Talanta* 2016, 150, 463-468. DOI: 10.1016/j.talanta.2015.12.072.
50. Goryacheva, I.Y.; Speranskaya, E. S.; Gofman, V.V.; Tang, D.; De Saeger, S. Synthesis and bioanalytical applications of nanostructures multiloaded with quantum dots. *TrAC* 2015, 66, 53-62
51. Lim, S.L.; Shen W.; Gao, Z. Carbon quantum dots and their applications. *Chem Soc Rev*, 2015, 44, 362-381 DOI: 10.1039/c4cs00269e
52. Li, Y.; Zhao, Y.; Cheng, H.; Hu, Y.; Shi, G.; Dai, L.; Qu, L.; Nitrogen-Doped Graphene Quantum Dots with Oxygen-Rich Functional Groups. *J Am Chem Soc* 2012, 134, 15-18 DOI: 10.1021/ja206030c
53. Sun, H.; Wu, P. Tuning the functional groups of carbon quantum dots in thin film nanocomposite membranes for nanofiltration. *J Membrane Sci* 2018, 564, 394-403
54. Fang, C.C.; Chou, C.C.; Yang, Y.Q.; Wei-Kai, T.; Wang, Y.T.; Chan, Y.H. Multiplexed Detection of Tumor Markers with Multicolor Polymer Dot-Based Immunochromatography Test Strip. *Anal Chem.* 2018, 90, 2134-2140. DOI: 10.1021/acs.analchem.7b04411